{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:08:24Z","timestamp":1793308104646,"version":"4.5.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403574"],"award-info":[{"award-number":["82403574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741470"],"award-info":[{"award-number":["2023M741470"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Association for Science & Technology Youth Science & Technology Talents Lifting Project","award":["JSTJ-2024-386"],"award-info":[{"award-number":["JSTJ-2024-386"]}]},{"name":"Research Project of Jiangsu Cancer Hospital","award":["ZJ202301"],"award-info":[{"award-number":["ZJ202301"]}]},{"name":"Research Project of Jiangsu Cancer Hospital","award":["SZL202301"],"award-info":[{"award-number":["SZL202301"]}]},{"name":"General Program of Wuxi Medical Center of Nanjing Medical University","award":["WMCG202354"],"award-info":[{"award-number":["WMCG202354"]}]},{"name":"General Program of Wuxi Medical Center of Nanjing Medical University","award":["WMCG202519"],"award-info":[{"award-number":["WMCG202519"]}]},{"name":"Doctoral Talent Fund of the Affiliated Wuxi People's Hospital of Nanjing Medical University","award":["BSRC202303"],"award-info":[{"award-number":["BSRC202303"]}]},{"name":"Research Project of Lianyungang Anti-Cancer Association","award":["ZD202312"],"award-info":[{"award-number":["ZD202312"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06660-7","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:46:00Z","timestamp":1750430760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Heterogeneous tissue-specific macrophages orchestrate metastatic organotropism of breast cancer: implications for promising therapeutics"],"prefix":"10.1186","volume":"23","author":[{"given":"Cenzhu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinchao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meican","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"8","key":"6660_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, et al. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708\u201328.","journal-title":"Cell"},{"issue":"10074","key":"6660_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet (London, England). 2017;389(10074):1134\u201350.","journal-title":"Lancet (London, England)"},{"key":"6660_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.978985","volume":"13","author":"J Fan","year":"2023","unstructured":"Fan J, et al. Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study. Front Oncol. 2023;13: 978985.","journal-title":"Front Oncol"},{"key":"6660_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"7966","key":"6660_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41586-023-06002-x","volume":"618","author":"T Lazarov","year":"2023","unstructured":"Lazarov T, et al. Physiology and diseases of tissue-resident macrophages. Nature. 2023;618(7966):698\u2013707.","journal-title":"Nature"},{"issue":"9","key":"6660_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41577-023-00848-y","volume":"23","author":"E Mass","year":"2023","unstructured":"Mass E, et al. Tissue-specific macrophages: how they develop and choreograph tissue biology. Nat Rev Immunol. 2023;23(9):563\u201379.","journal-title":"Nat Rev Immunol"},{"key":"6660_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153: 104683.","journal-title":"Pharmacol Res"},{"issue":"8","key":"6660_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cac2.12078","volume":"40","author":"S Ding","year":"2020","unstructured":"Ding S, et al. Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (London, England). 2020;40(8):329\u201344.","journal-title":"Cancer Commun (London, England)"},{"issue":"4","key":"6660_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10555-016-9639-8","volume":"35","author":"AR Chin","year":"2016","unstructured":"Chin AR, Wang SE. Cancer-derived extracellular vesicles: the \u2018soil conditioner\u2019 in breast cancer metastasis? Cancer Metastasis Rev. 2016;35(4):669\u201376.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"6660_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/cancers12071827","volume":"12","author":"GL Wong","year":"2020","unstructured":"Wong GL, et al. Exosomal MicroRNAs and organotropism in breast cancer metastasis. Cancers (Basel). 2020;12(7):1827.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"6660_CR11","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.3390\/ijms232213993","volume":"23","author":"S Huang","year":"2022","unstructured":"Huang S, et al. Tumor-derived exosomes and their role in breast cancer metastasis. Int J Mol Sci. 2022;23(22):13993.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6660_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13046-021-02164-6","volume":"40","author":"C Wang","year":"2021","unstructured":"Wang C, et al. Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer. J Exp Clin Cancer Res CR. 2021;40(1):370.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"6660_CR13","doi-asserted-by":"publisher","first-page":"111314","DOI":"10.1016\/j.biopha.2021.111314","volume":"137","author":"T Yu","year":"2021","unstructured":"Yu T, et al. Heterogeneity of CTC contributes to the organotropism of breast cancer. Biomed Pharmacother Biomed Pharmacother. 2021;137:111314.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"issue":"1","key":"6660_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13045-021-01198-9","volume":"14","author":"T Xu","year":"2021","unstructured":"Xu T, et al. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. J Hematol Oncol. 2021;14(1):181.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6660_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/PAP.0000000000000219","volume":"26","author":"M Akhtar","year":"2019","unstructured":"Akhtar M, et al. Paget\u2019s \u201cseed and soil\u201d theory of cancer metastasis: an idea whose time has come. Adv Anat Pathol. 2019;26(1):69\u201374.","journal-title":"Adv Anat Pathol"},{"issue":"7540","key":"6660_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature13989","volume":"518","author":"E Gomez Perdiguero","year":"2015","unstructured":"Gomez Perdiguero E, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518(7540):547\u201351.","journal-title":"Nature"},{"key":"6660_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad8670","author":"O Matcovitch-Natan","year":"2016","unstructured":"Matcovitch-Natan O, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016. https:\/\/doi.org\/10.1126\/science.aad8670.","journal-title":"Science"},{"issue":"6","key":"6660_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41593-019-0393-4","volume":"22","author":"H Van Hove","year":"2019","unstructured":"Van Hove H, et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat Neurosci. 2019;22(6):1021\u201335.","journal-title":"Nat Neurosci"},{"issue":"7907","key":"6660_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41586-022-04596-2","volume":"604","author":"T Masuda","year":"2022","unstructured":"Masuda T, et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature. 2022;604(7907):740\u20138.","journal-title":"Nature"},{"key":"6660_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.021","author":"SG Utz","year":"2020","unstructured":"Utz SG, et al. Early fate defines microglia and non-parenchymal brain macrophage development. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.03.021.","journal-title":"Cell"},{"key":"6660_CR21","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1126\/science.abf7844","volume":"373","author":"A Cugurra","year":"2021","unstructured":"Cugurra A, et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. 2021;373:6553.","journal-title":"Science"},{"key":"6660_CR22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210987","author":"E Evren","year":"2022","unstructured":"Evren E, et al. CD116+ fetal precursors migrate to the perinatal lung and give rise to human alveolar macrophages. J Exp Med. 2022. https:\/\/doi.org\/10.1084\/jem.20210987.","journal-title":"J Exp Med"},{"issue":"9","key":"6660_CR23","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.immuni.2022.08.010","volume":"55","author":"H Aegerter","year":"2022","unstructured":"Aegerter H, et al. Biology of lung macrophages in health and disease. Immunity. 2022;55(9):1564\u201380.","journal-title":"Immunity"},{"issue":"67","key":"6660_CR24","doi-asserted-by":"publisher","first-page":"eabf7777","DOI":"10.1126\/sciimmunol.abf7777","volume":"7","author":"SA Dick","year":"2022","unstructured":"Dick SA, et al. Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles. Sci Immunol. 2022;7(67):eabf7777.","journal-title":"Sci Immunol"},{"issue":"7753","key":"6660_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41586-019-1105-7","volume":"568","author":"CE Jacome-Galarza","year":"2019","unstructured":"Jacome-Galarza CE, et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature. 2019;568(7753):541\u20135.","journal-title":"Nature"},{"issue":"1","key":"6660_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-023-00469-0","volume":"13","author":"M Cao","year":"2024","unstructured":"Cao M, et al. The roles of tissue resident macrophages in health and cancer. Exp Hematol Oncol. 2024;13(1):3.","journal-title":"Exp Hematol Oncol"},{"key":"6660_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.07.018","author":"F Sierro","year":"2017","unstructured":"Sierro F, et al. A liver capsular network of monocyte-derived macrophages restricts hepatic dissemination of intraperitoneal bacteria by neutrophil recruitment. Immunity. 2017. https:\/\/doi.org\/10.1016\/j.immuni.2017.07.018.","journal-title":"Immunity"},{"key":"6660_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.08.009","author":"Z Liu","year":"2019","unstructured":"Liu Z, et al. Fate mapping via Ms4a3-expression history traces monocyte-derived cells. Cell. 2019. https:\/\/doi.org\/10.1016\/j.cell.2019.08.009.","journal-title":"Cell"},{"key":"6660_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.018","author":"M Guilliams","year":"2022","unstructured":"Guilliams M, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell. 2022. https:\/\/doi.org\/10.1016\/j.cell.2021.12.018.","journal-title":"Cell"},{"issue":"1","key":"6660_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"issue":"9","key":"6660_CR31","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425\u201340.","journal-title":"J Cell Physiol"},{"issue":"1","key":"6660_CR32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41467-020-15267-z","volume":"11","author":"L Bernier","year":"2020","unstructured":"Bernier L, et al. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. Nat Commun. 2020;11(1):1559.","journal-title":"Nat Commun"},{"issue":"3","key":"6660_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","volume":"19","author":"SK Wculek","year":"2022","unstructured":"Wculek SK, et al. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 2022;19(3):384\u2013408.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"6660_CR34","doi-asserted-by":"publisher","first-page":"21020","DOI":"10.1038\/s41598-020-77892-4","volume":"10","author":"J Taubmann","year":"2020","unstructured":"Taubmann J, et al. Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis. Sci Rep. 2020;10(1):21020.","journal-title":"Sci Rep"},{"issue":"7","key":"6660_CR35","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.7150\/thno.82700","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Pre-metastatic niche: from revealing the molecular and cellular mechanisms to the clinical applications in breast cancer metastasis. Theranostics. 2023;13(7):2301\u201318.","journal-title":"Theranostics"},{"issue":"8","key":"6660_CR36","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, et al. Metastasis. Cell. 2023;186(8):1564\u201379.","journal-title":"Cell"},{"issue":"3","key":"6660_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10555-020-09881-y","volume":"39","author":"M Hosonaga","year":"2020","unstructured":"Hosonaga M, et al. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39(3):711\u201320.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"6660_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101213","volume":"8","author":"K Riecke","year":"2023","unstructured":"Riecke K, et al. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. ESMO Open. 2023;8(3): 101213.","journal-title":"ESMO Open"},{"issue":"1","key":"6660_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-022-02535-7","volume":"41","author":"MM Caffarel","year":"2022","unstructured":"Caffarel MM, Braza MS. Microglia and metastases to the central nervous system: victim, ravager, or something else? J Exp Clin Cancer Res CR. 2022;41(1):327.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"7","key":"6660_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"key":"6660_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5791","author":"Z Yang","year":"2024","unstructured":"Yang Z, et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: a nonrandomized phase 2 trial. JAMA Oncol. 2024. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5791.","journal-title":"JAMA Oncol"},{"key":"6660_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae123","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, et al. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol. 2024. https:\/\/doi.org\/10.1093\/neuonc\/noae123.","journal-title":"Neuro Oncol"},{"issue":"1","key":"6660_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, et al. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6660_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.14336\/AD.2023.0514","volume":"15","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. The role of microglia in brain metastases: mechanisms and strategies. Aging Dis. 2024;15(1):169\u201385.","journal-title":"Aging Dis"},{"issue":"15","key":"6660_CR45","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.1158\/0008-5472.CAN-18-1102","volume":"78","author":"F Xing","year":"2018","unstructured":"Xing F, et al. Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 2018;78(15):4316\u201330.","journal-title":"Cancer Res"},{"issue":"12","key":"6660_CR46","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/neuonc\/noac136","volume":"24","author":"G Griguolo","year":"2022","unstructured":"Griguolo G, et al. A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro Oncol. 2022;24(12):2146\u201358.","journal-title":"Neuro Oncol"},{"issue":"1","key":"6660_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12974-020-01753-0","volume":"17","author":"A Simon","year":"2020","unstructured":"Simon A, et al. Metastatic breast cancer cells induce altered microglial morphology and electrical excitability in vivo. J Neuroinflammation. 2020;17(1):87.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"6660_CR48","volume":"38","author":"LD Strehle","year":"2024","unstructured":"Strehle LD, et al. Microglia contribute to mammary tumor-induced neuroinflammation in a female mouse model. FASEB J Off Public Fed Am Soc Exp Biol. 2024;38(2): e23419.","journal-title":"FASEB J Off Public Fed Am Soc Exp Biol"},{"issue":"12","key":"6660_CR49","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41568-021-00397-3","volume":"21","author":"BM Andersen","year":"2021","unstructured":"Andersen BM, et al. Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat Rev Cancer. 2021;21(12):786\u2013802.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6660_CR50","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41556-023-01273-y","volume":"25","author":"KT Evans","year":"2023","unstructured":"Evans KT, et al. Microglia promote anti-tumour immunity and suppress breast cancer brain metastasis. Nat Cell Biol. 2023;25(12):1848\u201359.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"6660_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13058-022-01514-2","volume":"24","author":"SL Foo","year":"2022","unstructured":"Foo SL, et al. Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1\/formyl peptide receptor signaling. Breast Cancer Res BCR. 2022;24(1):25.","journal-title":"Breast Cancer Res BCR"},{"key":"6660_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216879","volume":"591","author":"A Rivera-Ramos","year":"2024","unstructured":"Rivera-Ramos A, et al. Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth. Cancer Lett. 2024;591: 216879.","journal-title":"Cancer Lett"},{"issue":"1","key":"6660_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13058-021-01412-z","volume":"23","author":"S Wu","year":"2021","unstructured":"Wu S, et al. Tamoxifen suppresses brain metastasis of estrogen receptor-deficient breast cancer by skewing microglia polarization and enhancing their immune functions. Breast Cancer Research\u202f: BCR. 2021;23(1):35.","journal-title":"Breast Cancer Research : BCR"},{"issue":"10","key":"6660_CR54","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s43018-021-00254-0","volume":"2","author":"F Klemm","year":"2021","unstructured":"Klemm F, et al. Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. Nat Cancer. 2021;2(10):1086\u2013101.","journal-title":"Nat Cancer"},{"issue":"1","key":"6660_CR55","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1186\/s12885-021-09038-2","volume":"21","author":"S Lin","year":"2021","unstructured":"Lin S, et al. Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population. BMC Cancer. 2021;21(1):1330.","journal-title":"BMC Cancer"},{"issue":"3","key":"6660_CR56","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cam4.1370","volume":"7","author":"W Xiao","year":"2018","unstructured":"Xiao W, et al. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med. 2018;7(3):922\u201330.","journal-title":"Cancer Med"},{"issue":"1","key":"6660_CR57","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1038\/s41598-022-07565-x","volume":"12","author":"W Liu","year":"2022","unstructured":"Liu W, Han Y. Clinical outcomes and a nomogram for de novo metastatic breast cancer with lung metastasis: a population-based study. Sci Rep. 2022;12(1):3597.","journal-title":"Sci Rep"},{"issue":"7069","key":"6660_CR58","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u20137.","journal-title":"Nature"},{"issue":"5","key":"6660_CR59","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.7150\/thno.79250","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Tumor-derived Cav-1 promotes pre-metastatic niche formation and lung metastasis in breast cancer. Theranostics. 2023;13(5):1684\u201397.","journal-title":"Theranostics"},{"issue":"11","key":"6660_CR60","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.4049\/jimmunol.1403215","volume":"194","author":"SK Sharma","year":"2015","unstructured":"Sharma SK, et al. Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol. 2015;194(11):5529\u201338.","journal-title":"J Immunol"},{"key":"6660_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215667","volume":"537","author":"C Shang","year":"2022","unstructured":"Shang C, et al. CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis. Cancer Lett. 2022;537: 215667.","journal-title":"Cancer Lett"},{"issue":"4","key":"6660_CR62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s43018-022-00353-6","volume":"3","author":"T Hongu","year":"2022","unstructured":"Hongu T, et al. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nat Cancer. 2022;3(4):486\u2013504.","journal-title":"Nat Cancer"},{"issue":"12","key":"6660_CR63","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/2159-8290.CD-23-0299","volume":"13","author":"I Yofe","year":"2023","unstructured":"Yofe I, et al. Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary. Cancer Discov. 2023;13(12):2610\u201331.","journal-title":"Cancer Discov"},{"key":"6660_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160978","author":"ED Kramer","year":"2023","unstructured":"Kramer ED, et al. \u03b2-Catenin signaling in alveolar macrophages enhances lung metastasis through a TNF-dependent mechanism. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.160978.","journal-title":"JCI Insight"},{"issue":"8","key":"6660_CR65","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cam4.1668","volume":"7","author":"Y Gong","year":"2018","unstructured":"Gong Y, et al. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Med. 2018;7(8):4156\u201369.","journal-title":"Cancer Med"},{"issue":"1","key":"6660_CR66","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1186\/s12885-020-07593-8","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, et al. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. 2020;20(1):1102.","journal-title":"BMC Cancer"},{"issue":"3","key":"6660_CR67","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","volume":"101","author":"P Cl\u00e9zardin","year":"2021","unstructured":"Cl\u00e9zardin P, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797\u2013855.","journal-title":"Physiol Rev"},{"issue":"6","key":"6660_CR68","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cells10061377","volume":"10","author":"K Venetis","year":"2021","unstructured":"Venetis K, et al. Breast cancer with bone metastasis: molecular insights and clinical management. Cells. 2021;10(6):1377.","journal-title":"Cells"},{"issue":"3","key":"6660_CR69","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.7150\/thno.45351","volume":"11","author":"X Yuan","year":"2021","unstructured":"Yuan X, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics. 2021;11(3):1429\u201345.","journal-title":"Theranostics"},{"issue":"23","key":"6660_CR70","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/cancers14235727","volume":"14","author":"L Pang","year":"2022","unstructured":"Pang L, et al. Bone metastasis of breast cancer: molecular mechanisms and therapeutic strategies. Cancers (Basel). 2022;14(23):5727.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6660_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101165","volume":"4","author":"Y Wu","year":"2023","unstructured":"Wu Y, et al. Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis. Cell Rep Med. 2023;4(9): 101165.","journal-title":"Cell Rep Med"},{"issue":"8","key":"6660_CR72","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/jbmr.4615","volume":"37","author":"DL Arellano","year":"2022","unstructured":"Arellano DL, et al. Bone microenvironment-suppressed t cells increase osteoclast formation and osteolytic bone metastases in mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 2022;37(8):1446\u201363.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"20","key":"6660_CR73","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/0008-5472.CAN-20-3328","volume":"81","author":"H Zuo","year":"2021","unstructured":"Zuo H, et al. Fam20C regulates bone resorption and breast cancer bone metastasis through osteopontin and BMP4. Cancer Res. 2021;81(20):5242\u201354.","journal-title":"Cancer Res"},{"key":"6660_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.855609","volume":"12","author":"X Song","year":"2022","unstructured":"Song X, et al. The signaling pathways associated with breast cancer bone metastasis. Front Oncol. 2022;12: 855609.","journal-title":"Front Oncol"},{"issue":"6","key":"6660_CR75","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","volume":"20","author":"X Lu","year":"2011","unstructured":"Lu X, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging \u03b14\u03b21-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701\u201314.","journal-title":"Cancer Cell"},{"key":"6660_CR76","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1126\/scitranslmed.aai9338","volume":"9","author":"K Andrade","year":"2017","unstructured":"Andrade K, et al. RON kinase: a target for treatment of cancer-induced bone destruction and osteoporosis. Sci Transl Med. 2017;9:374.","journal-title":"Sci Transl Med"},{"issue":"6","key":"6660_CR77","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/ptr.7732","volume":"37","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, et al. Meso-Hannokinol inhibits breast cancer bone metastasis via the ROS\/JNK\/ZEB1 axis. Phytother Res PTR. 2023;37(6):2262\u201379.","journal-title":"Phytother Res PTR"},{"issue":"10","key":"6660_CR78","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.7150\/thno.29617","volume":"9","author":"P Jiang","year":"2019","unstructured":"Jiang P, et al. CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes\/macrophages. Theranostics. 2019;9(10):2950\u201366.","journal-title":"Theranostics"},{"issue":"12","key":"6660_CR79","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41416-022-02006-y","volume":"127","author":"M Zhang","year":"2022","unstructured":"Zhang M, et al. YTHDF2-mediated FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation. Br J Cancer. 2022;127(12):2141\u201353.","journal-title":"Br J Cancer"},{"key":"6660_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ctrv.2018.05.014","volume":"68","author":"X Wang","year":"2018","unstructured":"Wang X, et al. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treat Rev. 2018;68:62\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"6660_CR81","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/s41467-020-15429-z","volume":"11","author":"H Zuo","year":"2020","unstructured":"Zuo H, et al. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020;11(1):1578.","journal-title":"Nat Commun"},{"issue":"3","key":"6660_CR82","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/0008-5472.CAN-23-1443","volume":"84","author":"H Fan","year":"2024","unstructured":"Fan H, et al. Osteoclast cancer cell metabolic cross-talk confers PARP inhibitor resistance in bone metastatic breast cancer. Cancer Res. 2024;84(3):449\u201367.","journal-title":"Cancer Res"},{"issue":"1","key":"6660_CR83","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","volume":"7","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras DI, et al. Liver metastases. Nat Rev Dis Prim. 2021;7(1):27.","journal-title":"Nat Rev Dis Prim"},{"key":"6660_CR84","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.2147\/CMAR.S178395","volume":"10","author":"H Zhao","year":"2018","unstructured":"Zhao H, et al. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Manag Res. 2018;10:5937\u201350.","journal-title":"Cancer Manag Res"},{"key":"6660_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670723","volume":"11","author":"S Lin","year":"2021","unstructured":"Lin S, et al. Risk factors and survival of patients with liver metastases at initial metastatic breast cancer diagnosis in han population. Front Oncol. 2021;11: 670723.","journal-title":"Front Oncol"},{"issue":"2","key":"6660_CR86","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-021-06447-6","volume":"191","author":"TJ Honkanen","year":"2022","unstructured":"Honkanen TJ, et al. Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. Breast Cancer Res Treat. 2022;191(2):443\u201350.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6660_CR87","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12885-021-07968-5","volume":"21","author":"L Ji","year":"2021","unstructured":"Ji L, et al. Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer. 2021;21(1):238.","journal-title":"BMC Cancer"},{"issue":"24","key":"6660_CR88","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(24):5971\u201382.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7578","key":"6660_CR89","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino A, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329\u201335.","journal-title":"Nature"},{"issue":"7964","key":"6660_CR90","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41586-023-06114-4","volume":"618","author":"G Wang","year":"2023","unstructured":"Wang G, et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature. 2023;618(7964):374\u201382.","journal-title":"Nature"},{"key":"6660_CR91","doi-asserted-by":"publisher","first-page":"1043771","DOI":"10.3389\/fonc.2022.1043771","volume":"12","author":"C Liu","year":"2022","unstructured":"Liu C, et al. Breast cancer liver metastasis: pathogenesis and clinical implications. Front Oncol. 2022;12:1043771.","journal-title":"Front Oncol"},{"key":"6660_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157937","author":"W Liu","year":"2023","unstructured":"Liu W, et al. In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J Clin Investig. 2023. https:\/\/doi.org\/10.1172\/JCI157937.","journal-title":"J Clin Investig"},{"issue":"2","key":"6660_CR93","first-page":"188593","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. Progress and challenges of immunotherapy in triple-negative breast cancer. Rev Cancer. 2021;1876(2):188593.","journal-title":"Rev Cancer"},{"issue":"1","key":"6660_CR94","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","journal-title":"Mol Cancer"},{"issue":"1","key":"6660_CR95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22(1):145.","journal-title":"Mol Cancer"},{"key":"6660_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi7083","author":"M Siwicki","year":"2021","unstructured":"Siwicki M, et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol. 2021. https:\/\/doi.org\/10.1126\/sciimmunol.abi7083.","journal-title":"Sci Immunol"},{"issue":"11","key":"6660_CR97","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41590-023-01634-7","volume":"24","author":"J Li","year":"2023","unstructured":"Li J, et al. The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity. Nat Immunol. 2023;24(11):1813\u201324.","journal-title":"Nat Immunol"},{"issue":"8000","key":"6660_CR98","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41586-023-06950-4","volume":"626","author":"Z Deng","year":"2024","unstructured":"Deng Z, et al. The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature. 2024;626(8000):864\u201373.","journal-title":"Nature"},{"issue":"49","key":"6660_CR99","doi-asserted-by":"publisher","first-page":"14097","DOI":"10.1073\/pnas.1617903113","volume":"113","author":"Y Kimura","year":"2016","unstructured":"Kimura Y, et al. The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc Natl Acad Sci U S A. 2016;113(49):14097\u2013102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6660_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584458","volume":"11","author":"L Chen","year":"2020","unstructured":"Chen L, et al. Tumor-secreted GRP78 promotes the establishment of a pre-metastatic niche in the liver microenvironment. Front Immunol. 2020;11: 584458.","journal-title":"Front Immunol"},{"issue":"1","key":"6660_CR101","doi-asserted-by":"publisher","first-page":"17925","DOI":"10.1038\/s41598-017-17622-5","volume":"7","author":"LA Moraes","year":"2017","unstructured":"Moraes LA, et al. Annexin-A1 enhances breast cancer growth and migration by promoting alternative macrophage polarization in the tumour microenvironment. Sci Rep. 2017;7(1):17925.","journal-title":"Sci Rep"},{"issue":"7","key":"6660_CR102","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1541-7786.MCR-22-0673","volume":"21","author":"W Heo","year":"2023","unstructured":"Heo W, et al. Triple-negative breast cancer-derived extracellular vesicles promote a hepatic premetastatic niche via a cascade of microenvironment remodeling. Mol Cancer Res MCR. 2023;21(7):726\u201340.","journal-title":"Mol Cancer Res MCR"},{"issue":"1","key":"6660_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):127.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"6660_CR104","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, et al. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"6660_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"6660_CR106","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","volume":"44","author":"I Nasir","year":"2023","unstructured":"Nasir I, et al. Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies. Trends Immunol. 2023;44(12):971\u201385.","journal-title":"Trends Immunol"},{"key":"6660_CR107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175445","author":"C Dussold","year":"2024","unstructured":"Dussold C, et al. Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/JCI175445.","journal-title":"J Clin Investig"},{"key":"6660_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108031","volume":"234","author":"E Conte","year":"2022","unstructured":"Conte E. Targeting monocytes\/macrophages in fibrosis and cancer diseases: therapeutic approaches. Pharmacol Ther. 2022;234: 108031.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6660_CR109","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117.","journal-title":"Mol Cancer"},{"key":"6660_CR110","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, et al. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024;15:1385571.","journal-title":"Front Immunol"},{"issue":"7","key":"6660_CR111","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","volume":"24","author":"N Priego","year":"2018","unstructured":"Priego N, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24(7):1024\u201335.","journal-title":"Nat Med"},{"issue":"13","key":"6660_CR112","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner NM, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(13):3996\u20134013.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"6660_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217023","volume":"597","author":"AT Regua","year":"2024","unstructured":"Regua AT, et al. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Lett. 2024;597: 217023.","journal-title":"Cancer Lett"},{"issue":"4","key":"6660_CR114","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne IM, et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25(4):e139\u201351.","journal-title":"Lancet Oncol"},{"issue":"11","key":"6660_CR115","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/glia.23485","volume":"66","author":"R Blazquez","year":"2018","unstructured":"Blazquez R, et al. PI3K: a master regulator of brain metastasis-promoting macrophages\/microglia. Glia. 2018;66(11):2438\u201355.","journal-title":"Glia"},{"issue":"7","key":"6660_CR116","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nm.4120","volume":"22","author":"J Ni","year":"2016","unstructured":"Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22(7):723\u20136.","journal-title":"Nat Med"},{"issue":"7","key":"6660_CR117","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904\u201316.","journal-title":"Lancet Oncol"},{"issue":"15","key":"6660_CR118","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1158\/1078-0432.CCR-21-1549","volume":"27","author":"AML Wu","year":"2021","unstructured":"Wu AML, et al. Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(15):4422\u201334.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"12","key":"6660_CR119","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1021\/acs.molpharmaceut.0c00983","volume":"17","author":"SS Alhudaithi","year":"2020","unstructured":"Alhudaithi SS, et al. Local targeting of lung-tumor-associated macrophages with pulmonary delivery of a CSF-1R inhibitor for the treatment of breast cancer lung metastases. Mol Pharm. 2020;17(12):4691\u2013703.","journal-title":"Mol Pharm"},{"issue":"1","key":"6660_CR120","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19(1):165.","journal-title":"Mol Cancer"},{"issue":"20","key":"6660_CR121","doi-asserted-by":"publisher","first-page":"6556","DOI":"10.1158\/1078-0432.CCR-08-0711","volume":"14","author":"A S\u00e4fholm","year":"2008","unstructured":"S\u00e4fholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(20):6556\u201363.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"6660_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21083022","author":"S D'Oronzo","year":"2020","unstructured":"D\u2019Oronzo S, et al. Role of bone targeting agents in the prevention of bone metastases from breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21083022.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6660_CR123","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","volume":"26","author":"MFK Ibrahim","year":"2015","unstructured":"Ibrahim MFK, et al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(11):2205\u201313.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"35","key":"6660_CR124","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","volume":"35","author":"CL Shapiro","year":"2017","unstructured":"Shapiro CL, et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(35):3949\u201355.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"6660_CR125","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1093\/oncolo\/oyad338","volume":"29","author":"SA Piha-Paul","year":"2024","unstructured":"Piha-Paul SA, et al. First-in-human phase I study of tinengotinib (TT-00420), a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors. Oncologist. 2024;29(4):e514\u201325.","journal-title":"Oncologist"},{"issue":"5","key":"6660_CR126","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-021-04245-x","volume":"87","author":"F Lynce","year":"2021","unstructured":"Lynce F, et al. Phase I study of JAK1\/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021;87(5):673\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"6660_CR127","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-021-06306-4","volume":"189","author":"M Kearney","year":"2021","unstructured":"Kearney M, et al. Phase I\/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Res Treat. 2021;189(1):177\u201385.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6660_CR128","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41523-022-00487-x","volume":"8","author":"I Makhlin","year":"2022","unstructured":"Makhlin I, et al. Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer. NPJ Breast Cancer. 2022;8(1):122.","journal-title":"NPJ Breast Cancer"},{"issue":"21","key":"6660_CR129","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-20-0855","volume":"26","author":"KA Autio","year":"2020","unstructured":"Autio KA, et al. Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(21):5609\u201320.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"6660_CR130","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/annonc\/mdr261","volume":"23","author":"M Campone","year":"2012","unstructured":"Campone M, et al. Phase II study of single-agent bosutinib, a Src\/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(3):610\u20137.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"6660_CR131","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1093\/annonc\/mdr018","volume":"22","author":"MN Fornier","year":"2011","unstructured":"Fornier MN, et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(12):2575\u201381.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"6660_CR132","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-12-0652","volume":"19","author":"G Somlo","year":"2013","unstructured":"Somlo G, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(7):1884\u201393.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"23","key":"6660_CR133","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/1078-0432.CCR-15-2845","volume":"22","author":"Z Mitri","year":"2016","unstructured":"Mitri Z, et al. TBCRC-010: phase I\/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(23):5706\u201312.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"6660_CR134","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10549-018-05100-z","volume":"174","author":"A Ocana","year":"2019","unstructured":"Ocana A, et al. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM\/2010-04 study. Breast Cancer Res Treat. 2019;174(3):693\u2013701.","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"6660_CR135","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6660_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70302-X","author":"R Coleman","year":"2014","unstructured":"Coleman R, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 2014. https:\/\/doi.org\/10.1016\/S1470-2045(14)70302-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6660_CR137","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013;14(7):663\u201370.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6660_CR138","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4\u00a0Weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017;3(7):906\u201312.","journal-title":"JAMA Oncol"},{"issue":"1","key":"6660_CR139","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48\u201358.","journal-title":"JAMA"},{"issue":"8","key":"6660_CR140","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/2326-6066.CIR-13-0190","volume":"2","author":"A Swierczak","year":"2014","unstructured":"Swierczak A, et al. The promotion of breast cancer metastasis caused by inhibition of CSF-1R\/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol Res. 2014;2(8):765\u201376.","journal-title":"Cancer Immunol Res"},{"key":"6660_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0060-z","author":"DG Stover","year":"2018","unstructured":"Stover DG, et al. Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018. https:\/\/doi.org\/10.1038\/s41523-018-0060-z.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"6660_CR142","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-018-4770-6","volume":"170","author":"J O'Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy J, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res Treat. 2018;170(3):547\u201357.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6660_CR143","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13058-024-01774-0","volume":"26","author":"F Lynce","year":"2024","unstructured":"Lynce F, et al. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res BCR. 2024;26(1):20.","journal-title":"Breast Cancer Res BCR"},{"issue":"25","key":"6660_CR144","doi-asserted-by":"publisher","first-page":"12442","DOI":"10.1073\/pnas.1816410116","volume":"116","author":"EA Irey","year":"2019","unstructured":"Irey EA, et al. JAK\/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. Proc Natl Acad Sci U S A. 2019;116(25):12442\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6660_CR145","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","volume":"22","author":"AC Garrido-Castro","year":"2020","unstructured":"Garrido-Castro AC, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res BCR. 2020;22(1):120.","journal-title":"Breast Cancer Res BCR"},{"issue":"2","key":"6660_CR146","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-017-4596-7","volume":"168","author":"B Pistilli","year":"2018","unstructured":"Pistilli B, et al. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat. 2018;168(2):357\u201364.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"6660_CR147","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdw562","volume":"28","author":"M Mart\u00edn","year":"2017","unstructured":"Mart\u00edn M, et al. A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol Off J Eur Soc Med Oncol. 2017;28(2):313\u201320.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"6660_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30688-5","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018. https:\/\/doi.org\/10.1016\/S1470-2045(17)30688-5.","journal-title":"Lancet Oncol"},{"issue":"11","key":"6660_CR149","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/nox052","volume":"19","author":"AED Van Swearingen","year":"2017","unstructured":"Van Swearingen AED, et al. Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol. 2017;19(11):1481\u201393.","journal-title":"Neuro Oncol"},{"issue":"10","key":"6660_CR150","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ejca.2015.03.016","volume":"51","author":"K Zaman","year":"2015","unstructured":"Zaman K, et al. Fulvestrant with or without selumetinib, a MEK 1\/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21\/08. Eur J Cancer. 2015;51(10):1212\u201320.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6660_CR151","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184(1):53\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6660_CR152","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13058-022-01596-y","volume":"24","author":"J Luo","year":"2022","unstructured":"Luo J, et al. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res BCR. 2022;24(1):99.","journal-title":"Breast Cancer Res BCR"},{"issue":"2","key":"6660_CR153","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","volume":"36","author":"F Saad","year":"2010","unstructured":"Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev. 2010;36(2):177\u201384.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"6660_CR154","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","volume":"16","author":"EL Mayer","year":"2010","unstructured":"Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(14):3526\u201332.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"6660_CR155","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","volume":"11","author":"A Gucalp","year":"2011","unstructured":"Gucalp A, et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer. 2011;11(5):306\u201311.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"6660_CR156","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-023-06873-8","volume":"199","author":"AJ Oswald","year":"2023","unstructured":"Oswald AJ, et al. Aromatase inhibition plus\/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Res Treat. 2023;199(1):35\u201346.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6660_CR157","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1634\/theoncologist.2014-0021","volume":"19","author":"B Moy","year":"2014","unstructured":"Moy B, et al. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive\/HER2-negative breast cancer. Oncologist. 2014;19(4):348\u20139.","journal-title":"Oncologist"},{"issue":"11","key":"6660_CR158","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/bjc.2014.508","volume":"111","author":"SJ Isakoff","year":"2014","unstructured":"Isakoff SJ, et al. Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer. 2014;111(11):2058\u201366.","journal-title":"Br J Cancer"},{"issue":"21","key":"6660_CR159","doi-asserted-by":"publisher","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","volume":"17","author":"RS Finn","year":"2011","unstructured":"Finn RS, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(21):6905\u201313.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"21","key":"6660_CR160","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-11-0070","volume":"17","author":"EL Mayer","year":"2011","unstructured":"Mayer EL, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and\/or hormone receptor-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(21):6897\u2013904.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"18","key":"6660_CR161","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-11-1071","volume":"17","author":"CI Herold","year":"2011","unstructured":"Herold CI, et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(18):6061\u201370.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"6660_CR162","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-016-3911-z","volume":"159","author":"AF Schott","year":"2016","unstructured":"Schott AF, et al. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat. 2016;159(1):87\u201395.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6660_CR163","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clbc.2018.03.010","volume":"18","author":"PG Morris","year":"2018","unstructured":"Morris PG, et al. Phase II study of paclitaxel and dasatinib in metastatic breast cancer. Clin Breast Cancer. 2018;18(5):387\u201394.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"6660_CR164","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41590-023-01428-x","volume":"24","author":"T Wang","year":"2023","unstructured":"Wang T, et al. Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs. Nat Immunol. 2023;24(3):423\u201338.","journal-title":"Nat Immunol"},{"issue":"9","key":"6660_CR165","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/s41423-020-0449-0","volume":"18","author":"M Yu","year":"2021","unstructured":"Yu M, et al. Microwave ablation of primary breast cancer inhibits metastatic progression in model mice via activation of natural killer cells. Cell Mol Immunol. 2021;18(9):2153\u201364.","journal-title":"Cell Mol Immunol"},{"key":"6660_CR166","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002343","author":"W Zhou","year":"2021","unstructured":"Zhou W, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002343.","journal-title":"J Immunother Cancer"},{"key":"6660_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200033","author":"W Zhou","year":"2022","unstructured":"Zhou W, et al. Landscape of the peripheral immune response induced by local microwave ablation in patients with breast cancer. Adv Sci. 2022. https:\/\/doi.org\/10.1002\/advs.202200033.","journal-title":"Adv Sci"},{"issue":"1","key":"6660_CR168","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1038\/s41467-024-49059-6","volume":"15","author":"X Tang","year":"2024","unstructured":"Tang X, et al. Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. Nat Commun. 2024;15(1):4665.","journal-title":"Nat Commun"},{"key":"6660_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.01.015","author":"H Pan","year":"2024","unstructured":"Pan H, et al. Preoperative single-dose camrelizumab and\/or microwave ablation in women with early-stage breast cancer: a window-of-opportunity trial. Med. 2024. https:\/\/doi.org\/10.1016\/j.medj.2024.01.015.","journal-title":"Med"},{"issue":"1","key":"6660_CR170","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","volume":"6","author":"R Hirano","year":"2023","unstructured":"Hirano R, et al. Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases. Commun Biol. 2023;6(1):144.","journal-title":"Commun Biol"},{"issue":"3","key":"6660_CR171","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7053","volume":"13","author":"AK Elfstrum","year":"2024","unstructured":"Elfstrum AK, et al. Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer. Cancer Med. 2024;13(3): e7053.","journal-title":"Cancer Med"},{"key":"6660_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109047","volume":"110","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. The origins of resident macrophages in mammary gland influence the tumorigenesis of breast cancer. Int Immunopharmacol. 2022;110: 109047.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"6660_CR173","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41556-020-0505-0","volume":"22","author":"CA Dawson","year":"2020","unstructured":"Dawson CA, et al. Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling. Nat Cell Biol. 2020;22(5):546\u201358.","journal-title":"Nat Cell Biol"},{"key":"6660_CR174","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57438","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Tissue-resident macrophages promote extracellular matrix homeostasis in the mammary gland stroma of nulliparous mice. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.57438.","journal-title":"Elife"},{"key":"6660_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.02.021","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos R, et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022. https:\/\/doi.org\/10.1016\/j.cell.2022.02.021.","journal-title":"Cell"},{"key":"6660_CR176","doi-asserted-by":"publisher","DOI":"10.3791\/54306","author":"SK Vadrevu","year":"2016","unstructured":"Vadrevu SK, et al. Studying the role of alveolar macrophages in breast cancer metastasis. J Vis Exp JoVE. 2016. https:\/\/doi.org\/10.3791\/54306.","journal-title":"J Vis Exp JoVE"},{"key":"6660_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134808","author":"S Gutbier","year":"2020","unstructured":"Gutbier S, et al. Large-scale production of human iPSC-derived macrophages for drug screening. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21134808.","journal-title":"Int J Mol Sci"},{"key":"6660_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.004","author":"CS Mcginnis","year":"2024","unstructured":"Mcginnis CS, et al. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.004.","journal-title":"Cancer Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06660-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T16:02:35Z","timestamp":1750435355000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06660-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6660"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06660-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}